1.
|
17 p, 936.9 KB |
Hypoxia : the cornerstone of glioblastoma
/
Domènech Viñolas, Marta (Institut Català d'Oncologia) ;
Hernández, Ainhoa (Institut Català d'Oncologia) ;
Plaja, Andrea (Institut Català d'Oncologia) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Balañá, Carmen (Institut Català d'Oncologia)
Glioblastoma is the most aggressive form of brain tumor in adults and is characterized by the presence of hypervascularization and necrosis, both caused by a hypoxic microenvironment. In this review, we highlight that hypoxia-induced factor 1 (HIF-1), the main factor activated by hypoxia, is an important driver of tumor progression in GB patients. [...]
2021 - 10.3390/ijms222212608
International journal of molecular sciences, Vol. 22 Núm. 22 (november 2021) , p. 12608
|
|
2.
|
17 p, 2.4 MB |
Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients
/
Ruiz de Porras, V. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bystrup, Sara (Institut Germans Trias i Pujol) ;
Cabrero de las Heras, Sara (Institut Germans Trias i Pujol) ;
Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Palomero, L. (Institut d'Investigació Biomèdica de Bellvitge) ;
Alonso, M. H. (Universitat de Barcelona. Departament de Ciències Clíniques) ;
Nieto Raya, Rocio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno, V. (Universitat de Barcelona. Departament de Ciències Clíniques) ;
Queralt, C. (Institut Germans Trias i Pujol) ;
Manzano Mozo, José Luís (Institut Germans Trias i Pujol) ;
Layos, Laura (Institut Germans Trias i Pujol) ;
Bugés, Cristina (Institut Germans Trias i Pujol) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. [...]
2019 - 10.3390/cancers11101540
Cancers, Vol. 11 Núm. 10 (october 2019) , p. 1540
|
|
3.
|
18 p, 288.5 KB |
Translational research opportunities regarding homologous recombination in ovarian cancer
/
Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pardo, Juan Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quiroga, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Román, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ovarian carcinomas (HGSOC). Deficient HR (DHR) constitutes a therapeutic opportunity for these patients, thanks to poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi; olaparib, niraparib, and rucaparib are already commercialized). [...]
2018 - 10.3390/ijms19103249
International journal of molecular sciences, Vol. 19 Núm. 10 (19 2018) , p. 3249
|
|
4.
|
10 p, 1.9 MB |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
/
Codony-Servat, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cuatrecasas, Miriam ;
Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Montironi, Carla (Hospital Clínic i Provincial de Barcelona) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Marín Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Horndler, Carlos (Hospital Universitario Miguel Servet (Saragossa)) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ;
Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Reig, Oscar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Victoria, Iván (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gaba, Lydia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Fernández-Martos, Carlos (Fundació Institut Valencià d'Oncologia) ;
Feliu, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ;
Méndez, Jose Carlos (Centro Oncológico de Galicia) ;
Méndez, Miguel (Hospital Universitario de Móstoles (Madrid)) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
Salud, Antonieta (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Rojo, Federico (Fundacion Jimenez Diaz) ;
Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Universitat Autònoma de Barcelona
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786
|
|
5.
|
17 p, 2.9 MB |
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
/
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bystrup, Sara (Institut Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Pluvinet, Raquel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Sumoy, Lauro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Howells, Lynne (University of Leicester. Departament of Cancer Studies) ;
James, Mark I. (University of Leicester. Departament of Cancer Studies) ;
Iwuji, Chinenye (University of Leicester. Departament of Cancer Studies) ;
Manzano, José Luis (Institut Germans Trias i Pujol) ;
Layos, Laura (Institut Germans Trias i Pujol) ;
Bugés, Cristina (Institut Germans Trias i Pujol) ;
Abad, Albert (Hospital Cima Sanitas (Barcelona)) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic colorectal cancer (CRC) patients treated with this drug. De-regulation of the NF-κB signalling pathway has been proposed as an important mechanism involved in this phenomenon. [...]
2016 - 10.1038/srep24675
Scientific reports, Vol. 6 (April 2016)
|
|
6.
|
20 p, 10.3 MB |
PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines
/
Ginés Molina, Alba (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bystrup, Sara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Guardia, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Layos, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and also in patients. [...]
2015 - 10.1371/journal.pone.0123830
PloS one, Vol. 10, No. 5 (May 2015) , p. e0123830
|
|